Antimicrobial susceptibility of Moraxella catarrhalis isolated from children in KalgoorlieBoulder, Western Australia

Pathology

Volumn 42, Issue 3, 2010, Pages 273-279

  Pingault, Nevada M ^a   Bowman, Jacinta M ^b   Lehmann, Deborah ^c   Riley, Thomas V ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Path West Laboratory Medicine WA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antibiotic; Moraxella catarrhalis; Resistance; Western Australia

Indexed keywords

EID: 77950304860     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313021003631270     Document Type: Article

References (54)

1. Hays JP. The genus Moraxella. In: Dworkin M, Falkow S, Rosenberg E, Schleifer K, Stackebrandt E, editors. The Prokaryotes, A Handbook on the Biology of Bacteria. 3rd ed. New York: Springer, 2006; 958-987
2. Bluestone CD, Klein JO. Otitis Media in Infants and Children. 3rd ed. Philadelphia: Saunders, 2001.
3. Couzos S, Metcalf S, Murray R. Systematic Review of Existing Evidence and Primary Care Guidelines on the Management of Otitis Media in Aboriginal and Torres Strait Islander Populations. Canberra: Office of Aboriginal and Torres Strait Islander Health, Department of Health and Ageing, 2001.
4. Faden H, Duffy L, Wasielewski R, et al. Relationship between nasopharyngeal colonisation and the development of otitis media in children. J Infect Dis 1997; 175: 1440-1445
5. Leach AJ, Boswell JB, Asche V, et al. Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian Aboriginal infants. Pediatr Infect Dis J 1994; 13: 983-989
6. Malmvall B, Brorsson J, Johnsson J. In vitro sensitivity of penicillin V and b-lactamase production of Branhamella catarrhalis. J Antimicrob Chemother 1977; 3: 374-375
7. Ninane G, Joly J, Piot P, et al. Branhamella (Neisseria) catarrhalis as a pathogen. Lancet 1977; 2: 149.
8. Percival A, Corkill JE, Rowlands J, et al. Pathogenicity of and blactamase production by Branhamella (Neisseria) catarrhalis. Lancet 1977; 2: 1175.
9. McGregor K, Chang BJ, Mee BJ, et al. Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases. Eur J Clin Microbiol Infect Dis 1998; 17: 219-234
10. Digiovanni C, Riley TV, Hoyne GF, et al. Respiratory tract infections due to Branhamella catarrhalis: epidemiological data from Western Australia. Epidem Infect 1987; 99: 445-453
11. Riley TV, Digiovanni C. Susceptibility of Branhamella catarrhalis to tetracycline. J Antimicrob Chemother 1989; 23: 802-804
12. Wood GM, Johnson BC, McCormack JG. Moraxella catarrhalis: pathogenic significance in respiratory tract infections treated by community practitioners. Clin Infect Dis 1996; 22: 632-636
13. Lehmann D, Arumugaswamy A, Elsbury D, et al. The Kalgoorlie otitis media research project: rationale, methods, population characteristics and ethical considerations. Paediatr Perinat Epidemiol 2008; 22: 60-71.
14. Watson K, Carville K, Bowman J, et al. Upper respiratory tract bacterial carriage in Aboriginal and non Aboriginal children in a semiarid area of Western Australia. Pediatr Infect Dis J 2006; 25: 782-790
15. Murray, PR, Baron E, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of Clinical Microbiology. 8th ed. Washington: ASM Press, 2003.
16. Pingault NM, Lehmann D, Riley TV. Improved pulsed field gel electrophoresis method for Moraxella catarrhalis. J Microbiol Methods 2008; 75: 344-345
17. National Committee for Clinical Laboratory Standards (NCCLS). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Sixth Edition: Approved Standard M7-A6. Wayne, PA: NCCLS, 2003.
18. Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria-Approved Guideline M45-A. Wayne, PA: CLSI, 2006.
19. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement M100-S15. Wayne, PA: CLSI, 2005.
20. Montgomery K, Raymundo L, Drew WL. Chromagenic cephalosporin spot test to detect beta lactamase in clinically significant bacteria. J Clin Microbiol 1979; 9: 205-207
21. Gracia M, Diaz C, Coronel P, et al. Antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight central, east and Baltic European countries in 2005-2006: results of the cefditoren surveillance study. J Antimicrob Chemother 2008; 61: 1180-1185
22. Critchley IA, Brown SD, Traczewski MM, et al. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 US faropenem surveillance study. Antimicrob Agents Chemother 2007; 51: 4382-4389
23. Zemlickova H, Urbaskova P, Adamkova V, et al. Characteristics of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus isolated from the nasopharynx of healthy children attending day-care centres in the Czech Republic. Epidemiol Infect 2006; 134: 1179-1187
24. Inoue M, Kaneko K, Akizawa K, et al. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-3 (1999-2002). J Infect Chemother 2006; 12: 9-21.
25. Lau Y-J, Hsueh P-R, Liu Y-C, et al. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Taiwan. Microb Drug Resist 2006; 12: 130-135
26. Quinones D, Llanes R, Torano G, et al. Nasopharyngeal colonisation by Moraxella catarrhalis and study of antimicrobial susceptibility in healthy children from Cuban day-care centres. Arch Med Res 2005; 36: 80-82
27. Mendes C, Kiffer CRV, Blosser-Middleton RS, et al. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens - a Brazilian perspective from the GLOBAL surveillance initiative 2001-2002. Clin Microbiol Infect 2004; 10: 521-526
28. van Kempen MJP, Vaneechoutte M, Claeys G, et al. Antibiotic susceptibility of acute otitis media pathogens in otitis-prone Belgian children. Eur J Pediatr 2004; 163: 524-529
29. Reynolds R, Shackcloth J, Felmingham D, et al. Antimicrobial susceptibility of lower respiratory tract pathogens in Great Britain and Ireland 1999-2001 related to demographic and geographical factors: the BSAC respiratory resistance surveillance programme. J Antimicrob Chemother 2003; 52: 931-943
30. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1875-1881
31. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-246
32. Blondeau JM, Vaughan D, Laskowski R, et al. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents. Int J Antimicrob Agents 2001; 17: 457-464
33. Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program 1997-1999. Clin Infect Dis 2001; 32: S81-93.
34. Gur D, Ozalp M, Sumerkan B, et al. Prevalence of antimicrobial resistance in Haemophilus influenzae, Steptococcus pneumoniae, Moraxella catarrhalis and Streptococcus pyogenes: results of a multicentre study in Turkey. Int J Antimicrob Agents 2002; 19: 207-211
35. Beekmann SE, Heilmann KP, Richter SS, et al. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A b-haemolytic streptococci in 2002-2003, results of the multinational GRASP surveillance program. Int J Antimicrob Agents 2005; 25: 148-156
36. Biedenbach DJ, Jones RN, Fritsche TR. Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States. Diagn Microbiol Infect Dis 2008; 61: 240-244
37. Clawson Stone K, Dagan R, Arguedas A, et al. Activity of faropenem against middle ear fluid pathogens from children with acute otitis media in Costa Rica and Israel. Antimicrob Agents Chemother 2007; 51: 2230-2235
38. Gomi K, Watanabe A, Aoki S, et al. Antibacterial activity of carbapenems against clinically isolated respiratory bacterial pathogens in Japan between 2005 and 2006. Int J Antimicrob Agents 2007; 29: 586-592
39. Jones RN, Sader HS, Fritsche TR, et al. Comparsions of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY antimicrobial surveillance program (1998-2004). Diagn Microbiol Infect Dis 2007; 57: 109-116
40. Turnak MR, Bandak SI, Bouchillon SK, et al. Antimicrobial susceptibilities of clinical isolates of Haemophilus influenzae and Moraxella catarrhalis collected during 1999-2000 from 13 countries. Clin Microbiol Infect 2001; 7: 671-677
41. Nielsen HUK, Konradsen HB, Lous J, et al. Nasopharyngeal pathogens in children with acute otitis media in a low-antibiotic use country. Int J Pediatr Otorhinolaryngol 2004; 68: 1149-1155
42. Zheng X, Cao Y. Beta-lactamase-producing Branhamella in Beijing, China. Pediatr Infect Dis J 1988; 7: 744.
43. Brown BA, Wallace RJ, Flanagan CW, et al. Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother 1989; 33: 1631-1633
44. Roberts MC, Brown BA, Steingrube VA, et al. Genetic basis of tetracycline resistance in Moraxella (Branhamella) catarrhalis. Antimicrob Agents Chemother 1990; 34: 1816-1818.
45. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232-260
46. Karpanoja P, Nyberg ST, Bergman M, et al. Connection between trimethoprim-sulfamethoxazole use and resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 2008; 52: 2480-2485
47. Ahmad F, McLeod DT, Croughan MJ, et al. Antimicrobial susceptibility of Branhamella catarrhalis isolates from bronchopulmonary infections. Antimicrob Agents Chemother 1984; 26: 424-425
48. Riley TV, Digiovanni C, Hoyne GF. Susceptibility of Branhamella catarrhalis to sulphamethoxazole and trimethoprim. J Antimicrob Chemother 1987; 19: 39-43.
49. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008; 62 (Suppl 1): i1-9.
50. Viagappan M, Holliman RE. Risk factors for acquisition of gentamicin-resistant enterococcal infection: a case-controlled study. Postgrad Med J 1999; 75: 342-345
51. Graffunder EM, Preston KE, Evans AM, et al. Risk factors associated with extended-spectrum b-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother 2005; 56: 139-145
52. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics 2004; 113: 1451-1465
53. Expert Group - Antibiotic. Respiratory tract infections - other. In: Antibiotic Therapeutic Guidelines, Version 13. Victoria: Therapeutic Guidelines Limited, 2006; 236-240
54. Menzies School of Health Research. Recommendations for Clinical Care Guidelines on the Management of Otitis Media in Aboriginal and Torres Strait Islander Populations. Canberra: Office of Aboriginal and Torres Strait Islander Health, Department of Health and Ageing, 2001.